NL-OMON37134已完成不适用
A Phase 1, Randomized, Placebo- and Active-Controlled, Double-Blind, 4-Period Crossover ECG Study to Evaluate the Effect of VX 509 on QT/QTc Interval in Healthy Adult Subjects - VX-509 QTc study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male and female subjects
- •18-55 yrs, inclusive (part A)
- •18-45 yrs, inclusive (part B)
- •BMI: 18.0-31.0 kg/m2, inclusive
- •non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Placebo- and Active-Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of VX-661 on the QT/QTc Interval in Healthy Subjects10038686cystic fibrosisNL-OMON42529Vertex Pharmaceuticals130
已完成
1 期
A Phase 1 Exploratory Placebo and Active-Controlled, Double-Blind, Single and Multiple-Dose Escalation, Pharmacokinetic, Pharmacodynamic and Food Effect Study of CNSA-001 in Healthy VolunteersSegawa SyndromeACTRN12617001561370Censa Pharmaceuticals Australia Pty Ltd83
招募中
1 期
A Phase 1b, Randomized, Blinded, Placebo-Controlled Study toEvaluate the Effect of Selonsertib on Renal Function as Assessedby Markers of Glomerular Filtration Rate in Subjects with ChronicKidney DiseaseChronic Kidney DiseaseACTRN12618001377224Gilead Sciences60
进行中（未招募）
1 期
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveEUCTR2024-000122-18-Outside-EU/EEAModernaTX, Inc.
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyBacterial MeningitisMedDRA version: 14.0Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015198-11-DKPfizer Inc, 235 East 42nd Street, New York, NY 100177,500